Abstract: NOVELTY - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human zinc transporter 8 (ZnT8) sequence after optimal alignment, or at least one isolated antibody specific for the peptide, is used. USE - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes; and in vaccine for the treatment or prophylaxis of type I diabetes (claimed). ADVANTAGE - The method is more sensitive than the prior art method; and is able to allow to intervene in time with a treatment for preventing or delaying the onset of type I diabetes, for instance by avoiding, controlling or monitoring Mycobacterium avium paratuberculosis. DETAILED DESCRIPTION - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human ZnT8 sequence after optimal alignment, or at least one isolated antibody specific for the peptide; or a peptide selected from at least one isolated peptide belonging to ZnT8 sequence having amino acids 174-194, peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to MAP3865c from amino acids 121-141, or isolated antibodies specific for the peptide, as biomarkers in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, is used. INDEPENDENT CLAIMS are included for the following: 1) new isolated nucleic acid molecule encoding for the peptide; 2) new vector comprising the nucleic acid molecule; new isolated cell comprising the vector; 3) a kit comprising a container containing the peptide or the nucleic acid molecule; 4) new isolated antibody specific for the peptide; 5) use of vaccine comprising the isolated peptide for the treatment or prophylaxis of type I diabetes; and 6) use of anti Mycobacterium avium paratuberculosis drugs in the prevention and treatment of type I diabetes.

Use of isolated peptide belonging to Mycobacterium avium paratuberculosis, having specific homology, or isolated antibody, as biomarker in an in vitro test for diagnosing individual who is susceptible to or who is developing type I diabetes / Sechi, Leonardo Antonio; Mallone, R.. - (2013).

Use of isolated peptide belonging to Mycobacterium avium paratuberculosis, having specific homology, or isolated antibody, as biomarker in an in vitro test for diagnosing individual who is susceptible to or who is developing type I diabetes

SECHI, Leonardo Antonio;
2013-01-01

Abstract

Abstract: NOVELTY - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human zinc transporter 8 (ZnT8) sequence after optimal alignment, or at least one isolated antibody specific for the peptide, is used. USE - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes; and in vaccine for the treatment or prophylaxis of type I diabetes (claimed). ADVANTAGE - The method is more sensitive than the prior art method; and is able to allow to intervene in time with a treatment for preventing or delaying the onset of type I diabetes, for instance by avoiding, controlling or monitoring Mycobacterium avium paratuberculosis. DETAILED DESCRIPTION - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human ZnT8 sequence after optimal alignment, or at least one isolated antibody specific for the peptide; or a peptide selected from at least one isolated peptide belonging to ZnT8 sequence having amino acids 174-194, peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to MAP3865c from amino acids 121-141, or isolated antibodies specific for the peptide, as biomarkers in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, is used. INDEPENDENT CLAIMS are included for the following: 1) new isolated nucleic acid molecule encoding for the peptide; 2) new vector comprising the nucleic acid molecule; new isolated cell comprising the vector; 3) a kit comprising a container containing the peptide or the nucleic acid molecule; 4) new isolated antibody specific for the peptide; 5) use of vaccine comprising the isolated peptide for the treatment or prophylaxis of type I diabetes; and 6) use of anti Mycobacterium avium paratuberculosis drugs in the prevention and treatment of type I diabetes.
2013
Use of isolated peptide belonging to Mycobacterium avium paratuberculosis, having specific homology, or isolated antibody, as biomarker in an in vitro test for diagnosing individual who is susceptible to or who is developing type I diabetes / Sechi, Leonardo Antonio; Mallone, R.. - (2013).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/88218
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact